Boston Scientific Corporation

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Boston Scientific Corporation sits in the top decile of US sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count).

280 total trials 22 currently recruiting 207 completed later-stage tilt top decile by trial count

Boston Scientific Corporation: 280 sponsored US clinical trials, 22 recruiting.

Boston Scientific Corporation sponsors 280 registered US clinical trials on ClinicalTrials.gov, 22 of them currently recruiting, and 207 completed. 59 of these trials are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Coronary Artery Disease, with 8 trials.

Top-decile sponsor footprint

Boston Scientific Corporation ranks in the top decile of sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

207 of 239 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

280 total, page 4 of 6

TERMINATED NA

Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE

NCT01775735
COMPLETED

Longitudinal Surveillance Study of the 4-SITE Lead/Header System

NCT01596595
COMPLETED

S-ICD® System Post Approval Study

NCT01736618
COMPLETED NA

Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer

NCT01774019
COMPLETED NA

ImageReady(TM) MR Conditional Pacing System Clinical Study

NCT01781078
COMPLETED NA

Evaluation of PCLs Using Three EUS-FNA Needles

NCT01711294
COMPLETED Phase 3

The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)

NCT01665053
COMPLETED NA

Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation

NCT01687166
COMPLETED NA

Safety and Performance Study of the INGEVITY Lead

NCT01688843
TERMINATED NA

Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study

NCT01608490
COMPLETED NA

Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology

NCT01760291
TERMINATED NA

Embozene Microspheres for Uterine Fibroid Embolization (UFE)

NCT01675011
COMPLETED NA

Randomized Study of Failed SCS Trials Comparing Outcomes Using the Observational Mechanical Gateway (OMG) Connector

NCT01643213
COMPLETED Phase 3

Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter

NCT01635881
COMPLETED Phase 3

Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy

NCT01513759
COMPLETED NA

High Rate Spinal Cord Stimulation (SCS) for Chronic Pain

NCT01624740
COMPLETED

Multiple Areas of Pain (MAP)

NCT01583894
COMPLETED Phase 4

PROMUS Element Plus US Post-Approval Study

NCT01589978
COMPLETED NA

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

NCT01556490
COMPLETED

ELEVATE (Evaluation of Left Ventricular Autothreshold) 3.0

NCT01539629
COMPLETED NA

Safety and Efficacy of Cryoablation for Metastatic Lung Tumors

NCT01307501
COMPLETED NA

Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer

NCT01483027
COMPLETED Phase 3

SpaceOAR System Pivotal Study

NCT01538628
COMPLETED Phase 1

Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases

NCT01461265
COMPLETED NA

The OMEGA Clinical Trial

NCT01419171
COMPLETED Phase 4

The Jetstream (JET) Post-market Registry

NCT01436435
COMPLETED

ION US Post-Approval Study

NCT01422889
COMPLETED Phase 1

Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)

NCT01428076
TERMINATED Phase 1

Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer

NCT01335945
COMPLETED

PROPPER Prospective Registry of Outcomes With Penile Prosthesis

NCT01383018
COMPLETED

Physiological Response to Exercise: Sensor Evaluation at Specified Exertions

NCT01229137
COMPLETED NA

Bronchial Thermoplasty in Severe Persistent Asthma

NCT01350336
COMPLETED NA

SuperNOVA Clinical Stenting Trial

NCT01292928
COMPLETED

Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy Post Approval Registry

NCT01294449
COMPLETED NA

Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter

NCT01253200
COMPLETED Phase 4

The Jetstream G3™ Calcium Study

NCT01273623
COMPLETED Phase 3

Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

NCT01072877
COMPLETED Phase 3

Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

NCT01231373
COMPLETED

Evaluation of Left Ventricular Autothreshold, Phase Two

NCT01242722
COMPLETED Phase 3

Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

NCT01182441
COMPLETED Phase 3

Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities

NCT01197833
TERMINATED

Tracking Renal Tumors After Cryoablation Evaluation

NCT01117779
COMPLETED

Evaluation of Multisensor Data in Heart Failure Patients With Implanted Devices

NCT01128166
TERMINATED Phase 4

Spinal Cord Stimulation With Precision® System Versus Reoperation for Failed Back Surgery Syndrome

NCT01036529
COMPLETED NA

S-ICD® System IDE Clinical Study

NCT01064076
COMPLETED

Registry of AngioJet Use in the Peripheral Vascular System

NCT01086215
COMPLETED

Bion Occipital Nerve Stimulation (ONS) Compassionate Use Study

NCT01050959
COMPLETED

TAXUS Libertē Post Approval Study

NCT00997503
COMPLETED

Common Sensing and Right Ventricular Automatic Capture (COGNATE)

NCT01030705
COMPLETED NA

WallFlex Biliary Post Liver Transplant IDE Pilot

NCT01151280
← Previous Page 4 of 6 Next →

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 16
Phase 3 33
Phase 4 26

Therapeutic Areas

Coronary Artery Disease 8
Chronic Pain 8
Varicose Veins 5
Paroxysmal Atrial Fibrillation 5
Atrial Fibrillation 4
Bleeding 3
Atherosclerosis 3
Heart Failure 3
Ventricular Fibrillation 2
Tachycardia 2

Where Boston Scientific Corporation enrollment is open (later-stage tilt)

22 recruiting of 280 indexed (8% open); 207 completed (74%).

Phase mix: 59 late (III/IV) vs 23 early (I/II) (later-stage heavy).

Top condition: Coronary Artery Disease (8 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Boston Scientific Corporation: open-pipeline peers nationwide

Peers matched on 280 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

Boston Scientific Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 0%5%10%15%20%25% Total trials Recruiting share Boston Scientific CorporationRegeneron PharmaceuticalsAlcon ResearchEisaiSWOG Cancer Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Novo Nordisk A/SHoffmann-La RocheUnited Therapeutics
Boston Scientific Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Boston Scientific Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 280 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Boston Scientific Corporation page

280 registered trials is a research-attention snapshot, not an endorsement of Boston Scientific Corporation or any single study.

  • 22 of Boston Scientific Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Coronary Artery Disease is the condition Boston Scientific Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Coronary Artery Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Boston Scientific Corporation pipeline card: 280 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.